Reminds me of a stock I used to hold - PCK. PainChek was bringing in an entirely new process for the medical industry to gauge pain. Unfortunately, they struggled to get workers in the health industry to see value in the new process - even though, from a thereotical point of view it was better. The difference with Febridx, I hope, is that there is a real global health issue around misdiagnosis of antibiotics that will motivate the need for change/uptake.
Guess for upcoming quarterly, page-16
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
